Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children

ClinicalTrials.gov ID: NCT00102817

Public ClinicalTrials.gov record NCT00102817. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Somatropin (Norditropin) in Children With Growth Failure Associated With ICF Deficiency.

Study identification

NCT ID
NCT00102817
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
149 participants

Conditions and interventions

Interventions

  • somatropin Drug

Drug

Eligibility (public fields only)

Age range
3 Years to 13 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2003
Primary completion
Nov 30, 2006
Completion
Nov 30, 2006
Last update posted
Jan 17, 2017

2003 – 2006

United States locations

U.S. sites
27
U.S. states
15
U.S. cities
26
Facility City State ZIP Site status
Novo Nordisk Investigational Site Los Angeles California 90027
Novo Nordisk Investigational Site San Diego California 92093
Novo Nordisk Investigational Site Stanford California 94305-5208
Novo Nordisk Investigational Site St. Petersburg Florida 33701
Novo Nordisk Investigational Site Tallahassee Florida 32308
Novo Nordisk Investigational Site Tampa Florida 33607
Novo Nordisk Investigational Site Indianapolis Indiana 46202-5225
Novo Nordisk Investigational Site Boston Massachusetts 02115
Novo Nordisk Investigational Site Worcester Massachusetts 01655
Novo Nordisk Investigational Site Kalamazoo Michigan 49008
Novo Nordisk Investigational Site Minneapolis Minnesota 55416
Novo Nordisk Investigational Site Kansas City Missouri 64108
Novo Nordisk Investigational Site Brooklyn New York 11219
Novo Nordisk Investigational Site Buffalo New York 14222
Novo Nordisk Investigational Site Rockville Centre New York 11570
Novo Nordisk Investigational Site The Bronx New York 10467
Novo Nordisk Investigational Site Akron Ohio 44308-1062
Novo Nordisk Investigational Site Cincinnati Ohio 45229
Novo Nordisk Investigational Site Oklahoma City Oklahoma 73104
Novo Nordisk Investigational Site Hershey Pennsylvania 17033
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19104
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19107
Novo Nordisk Investigational Site Pittsburgh Pennsylvania 15213
Novo Nordisk Investigational Site Columbia South Carolina 29203
Novo Nordisk Investigational Site San Antonio Texas 78284
Novo Nordisk Investigational Site Seattle Washington 98105
Novo Nordisk Investigational Site Milwaukee Wisconsin 53226-0509

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00102817, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 17, 2017 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00102817 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →